Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
2.500
-0.210 (-7.75%)
At close: Jun 27, 2025, 4:00 PM
2.600
+0.100 (4.00%)
After-hours: Jun 27, 2025, 7:53 PM EDT
Jaguar Health Employees
Jaguar Health had 49 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
49
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$235,755
Profits / Employee
-$810,816
Market Cap
3.31M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
JAGX News
- 2 days ago - Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset - Accesswire
- 3 days ago - Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs - Accesswire
- 4 days ago - Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026 - Accesswire
- 5 days ago - Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer - Accesswire
- 11 days ago - Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts - Accesswire
- 17 days ago - First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - Accesswire
- 19 days ago - REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series - Accesswire
- 19 days ago - Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer - Accesswire